David W Denning

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/299534/david-w-denning-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

621 57,961 228 100 h-index g-index citations papers 66,791 7.88 691 7.5 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
621	Prospective Evaluation of Positivity Rates of -Specific IgG and Quality of Life in HIV-Negative Tuberculosis Patients in Lagos, Nigeria <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12, 79013	4 ^{5.9}	O
620	Antifungal drug resistance: an update European Journal of Hospital Pharmacy, 2022, 29, 109-112	1.6	1
619	Histoplasmosis in Africa: Current perspectives, knowledge gaps, and research priorities <i>PLoS Neglected Tropical Diseases</i> , 2022 , 16, e0010111	4.8	1
618	Pulmonary and Extrapulmonary Manifestations of Fungal Infections Misdiagnosed as Tuberculosis: The Need for Prompt Diagnosis and Management. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022 , 8, 460	5.6	2
617	A global call for talaromycosis to be recognised as a neglected tropical disease. <i>The Lancet Global Health</i> , 2021 , 9, e1618-e1622	13.6	4
616	Defective interferon-gamma production is common in chronic pulmonary aspergillosis. <i>Journal of Infectious Diseases</i> , 2021 ,	7	2
615	One Health aspects & priority roadmap for fungal diseases : A mini-review. <i>Indian Journal of Medical Research</i> , 2021 , 153, 311-319	2.9	2
614	Standardization of IgG diagnostic cutoff in Nigerians. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 20499361211050158	2.8	0
613	Risk factors associated with respiratory infectious disease-related presenteeism: a rapid review. <i>BMC Public Health</i> , 2021 , 21, 1955	4.1	6
612	Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis. <i>Respiratory Medicine</i> , 2021 , 178, 1062	290 ⁶	3
611	A Rapid Screening Program for Histoplasmosis, Tuberculosis, and Cryptococcosis Reduces Mortality in HIV Patients from Guatemala. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	6
610	Histoplasmosis in the Republic of Congo dominated by African histoplasmosis, Histoplasma capsulatum var. duboisii. <i>PLoS Neglected Tropical Diseases</i> , 2021 , 15, e0009318	4.8	4
609	Fungal asthma among Ugandan adult asthmatics. <i>Medical Mycology</i> , 2021 , 59, 923-933	3.9	O
608	Evaluation of an Aspergillus IgG/IgM lateral flow assay for serodiagnosis of fungal asthma in Uganda. <i>PLoS ONE</i> , 2021 , 16, e0252553	3.7	0
607	Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detection enzyme immunoassay: A pilot study in Cameroon. <i>Journal of Microbiological Methods</i> , 2021 , 185, 10622	6 ^{2.8}	2
606	Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 767	25.5	4
605	Serious fungal disease incidence and prevalence in Indonesia. <i>Mycoses</i> , 2021 , 64, 1203-1212	5.2	1

(2021-2021)

604	Serious fungal diseases in Democratic Republic of Congo - Incidence and prevalence estimates. <i>Mycoses</i> , 2021 , 64, 1159-1169	5.2	1
603	Histoplasmosis in Children; HIV/AIDS Not a Major Driver. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	2
602	Chronic Pulmonary Aspergillosis Situation among Post Tuberculosis Patients in Vietnam: An Observational Study. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	2
601	Determining the burden of fungal infections in Zimbabwe. <i>Scientific Reports</i> , 2021 , 11, 13240	4.9	1
600	Characterisation of Endocytic Trafficking within Airway Epithelial Cells Using High-Resolution Automated Quantitative Confocal Microscopy. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	4
599	Impact of the COVID-19 pandemic on HIV care in Guatemala. <i>International Journal of Infectious Diseases</i> , 2021 , 108, 422-427	10.5	4
598	The global incidence and diagnosis of fungal keratitis. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e49-e57	25.5	51
597	The burden of serious fungal infections in Azerbaijan. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 20499361211043969	2.8	O
596	The burden of serious fungal infections in Sierra Leone: a national estimate. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 20499361211027996	2.8	Ο
595	Ending deaths from HIV-related cryptococcal meningitis by 2030. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 16-18	25.5	5
594	Drug-drug interaction database for safe prescribing of systemic antifungal agents. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 20499361211010605	2.8	
593	Fungal infections in transplant recipients: pros and cons of immunosuppressive and antimicrobial treatment <i>Lancet Microbe, The</i> , 2021 , 2, e6-e8	22.2	Ο
592	The global burden of chromoblastomycosis. <i>PLoS Neglected Tropical Diseases</i> , 2021 , 15, e0009611	4.8	6
591	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , 2021 , 8, of about 10 of 10 o	4 ¹ 41	O
590	Estimated burden of serious fungal infections in Togo. <i>Mycoses</i> , 2021 , 64, 1535-1541	5.2	1
589	Prevalence of skin positivity in adults without an apparent/known atopic disease in Uganda. <i>Therapeutic Advances in Infectious Disease</i> , 2021 , 8, 20499361211039040	2.8	O
588	Evaluation of multiple open-source deep learning models for detecting and grading COVID-19 on chest radiographs <i>Journal of Medical Imaging</i> , 2021 , 8, 064502	2.6	
587	Incidence of Histoplasmosis in a Cohort of People with HIV: From Estimations to Reality <i>Microorganisms</i> , 2021 , 9,	4.9	1

586	Impact of high baseline Aspergillus-specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis. <i>Medical Mycology</i> , 2020 , 58, 1000-1004	3.9	1
585	Chronic Pulmonary Histoplasmosis-A Scoping Literature Review. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa119	1	9
584	The antiseptic Miramistin: a review of its comparative in vitro and clinical activity. <i>FEMS Microbiology Reviews</i> , 2020 , 44, 399-417	15.1	9
583	Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture. <i>MBio</i> , 2020 , 11,	7.8	94
582	Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically. <i>European Journal of Cardio-thoracic Surgery</i> , 2020 , 58, 997-1003	3	7
581	Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and meta-analysis. <i>Mycoses</i> , 2020 , 63, 921-927	5.2	4
580	Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	13
579	European confederation of medical mycology expert consult-An ECMM excellence center initiative. <i>Mycoses</i> , 2020 , 63, 566-572	5.2	2
578	Current burden of serious fungal infections in Republic of Congo. <i>Mycoses</i> , 2020 , 63, 543-552	5.2	3
577	Re-drawing the Maps for Endemic Mycoses. <i>Mycopathologia</i> , 2020 , 185, 843-865	2.9	61
576	Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 1125-1132	10.2	16
575	Integration of fungal diseases into health systems in Latin America. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 890-892	25.5	2
574	Tackling cryptococcal meningitis in Nigeria, one-step at a time; the impact of training. <i>PLoS ONE</i> , 2020 , 15, e0235577	3.7	3
573	Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy. <i>Clinical Infection in Practice</i> , 2020 , 5, 100015	1	5
572	Mycetoma in Uganda: A neglected tropical disease. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e00082	40 4.8	16
571	Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis: effects on frequency of acute exacerbation and all-cause hospital admission. <i>Thorax</i> , 2020 , 75, 513-516	7.3	6
570	Evaluation of knowledge and awareness of invasive fungal infections amongst resident doctors in Nigeria. <i>Pan African Medical Journal</i> , 2020 , 36, 297	1.2	5
569	Opportunistic fungal infections in persons living with advanced HIV disease in Lagos, Nigeria; a 12-year retrospective study. <i>African Health Sciences</i> , 2020 , 20, 1573-1581	1.1	1

(2020-2020)

568	Prophylaxis and Treatment of Invasive Aspergillosis: Who and How of Prophylaxis, Treatment, and New Therapies. <i>Current Treatment Options in Infectious Diseases</i> , 2020 , 12, 54-70	1	
567	Estimated Burden of Fungal Infections in Oman. Journal of Fungi (Basel, Switzerland), 2020, 7,	5.6	1
566	Skin prick reactivity among asthmatics in East Africa. World Allergy Organization Journal, 2020, 13, 1001	35 02	6
565	The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz534	1	13
564	Linking calcium signaling and mitochondrial function in fungal drug resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 1254-1256	11.5	6
563	Bridging the knowledge gap on mycoses in Africa: Setting up a Pan-African Mycology Working Group. <i>Mycoses</i> , 2020 , 63, 244-249	5.2	8
562	The global distribution of actinomycetoma and eumycetoma. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0008397	4.8	12
561	The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. <i>Fungal Biology Reviews</i> , 2020 , 34, 202-214	6.8	30
560	The role of antifungals in the management of patients with severe asthma. <i>Clinical and Translational Allergy</i> , 2020 , 10, 46	5.2	12
559	Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020 , 98, 115124	2.9	4
558	Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV. <i>Aids</i> , 2020 , 34, 1625-1632	3.5	10
557	Optimising the cut-off of the Bordier Aspergillus IgG ELISA for the diagnosis of chronic pulmonary aspergillosis. <i>Journal of Microbiological Methods</i> , 2020 , 176, 106021	2.8	3
556	Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin. Journal of Global Antimicrobial Resistance, 2020, 23, 284-285	3.4	2
555	Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2. <i>British Dental Journal</i> , 2020 , 229, 521-524	1.2	9
554	Deciphering Aspergillus fumigatus cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3501-3509	5.1	3
553	Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis. <i>PLoS ONE</i> , 2020 , 15, e0238855	3.7	9
552	The global impact of Aspergillus infection on COPD. BMC Pulmonary Medicine, 2020, 20, 241	3.5	17
551	The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis. <i>Naunyn-Schmiedebergh Archives of Pharmacology</i> , 2020 , 393, 2233-223	7 ^{3.4}	1

550	Risk-Based Estimate of Human Fungal Disease Burden, China. <i>Emerging Infectious Diseases</i> , 2020 , 26, 2137-2147	10.2	8
549	Recovery from Copperhead Snake Envenomation: Role of Age, Sex, Bite Location, Severity, and Treatment. <i>Journal of Medical Toxicology</i> , 2020 , 16, 17-23	2.6	2
548	Burden of serious fungal infections in the Netherlands. <i>Mycoses</i> , 2020 , 63, 625-631	5.2	15
547	Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis 2020 , 15, e0238855		
546	Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis 2020 , 15, e0238855		
545	Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis 2020 , 15, e0238855		
544	Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis 2020 , 15, e0238855		
543	Estimated Burden of Fungal Infections in Namibia. Journal of Fungi (Basel, Switzerland), 2019, 5,	5.6	8
542	Getting Histoplasmosis on the Map of International Recommendations for Patients with Advanced HIV Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5,	5.6	12
541	The Diagnosis of Fungal Neglected Tropical Diseases (Fungal NTDs) and the Role of Investigation and Laboratory Tests: An Expert Consensus Report. <i>Tropical Medicine and Infectious Disease</i> , 2019 , 4,	3.5	22
540	Fungal Diseases in Taiwan-National Insurance Data and Estimation. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5,	5.6	3
539	Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	55
538	Evaluation of LDBio ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	19
537	Stress-Induced Changes in the Lipid Microenvironment of E(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus. <i>MBio</i> , 2019 , 10,	7.8	23
536	Estimated Burden of Serious Fungal Infections in Ghana. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5,	5.6	7
535	The case for paracoccidioidomycosis to be accepted as a neglected tropical (fungal) disease. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007195	4.8	24
534	Burden of fungal asthma in Africa: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2019 , 14, e021656	- - 5 8 .7	26
533	Detection of Pneumocystis jirovecii by quantitative real-time PCR in oral rinses from Pneumocystis pneumonia asymptomatic human immunodeficiency virus patients. <i>Journal De Mycologie Medicale</i> , 2019 , 29, 107-111	3	5

532	Pathophysiological aspects of Aspergillus colonization in disease. <i>Medical Mycology</i> , 2019 , 57, S219-S22	7 3.9	40
531	The validity, reliability and minimal clinically important difference of the patient specific functional scale in snake envenomation. <i>PLoS ONE</i> , 2019 , 14, e0213077	3.7	11
530	Siemens Immulite Aspergillus-specific IgG assay for chronic pulmonary aspergillosis diagnosis. <i>Medical Mycology</i> , 2019 , 57, 300-307	3.9	16
529	Estimated burden of serious human fungal diseases in Turkey. <i>Mycoses</i> , 2019 , 62, 22-31	5.2	10
528	Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis. <i>BMC Infectious Diseases</i> , 2019 , 19, 694	4	8
527	National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 1121-1134	3.8	3
526	Estimated burden of fungal infections in Sweden. <i>Mycoses</i> , 2019 , 62, 1043-1048	5.2	6
525	The Burden of Serious Fungal Infections in Kyrgyzstan. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5,	5.6	2
524	The Burden of Serious Fungal Infections in Tajikistan. Journal of Fungi (Basel, Switzerland), 2019, 5,	5.6	2
523	Mapping histoplasmosis in South East Asia - implications for diagnosis in AIDS. <i>Emerging Microbes and Infections</i> , 2019 , 8, 1139-1145	18.9	18
523 522		18.9 5.2	18
	and Infections, 2019 , 8, 1139-1145 An evaluation of nebulised amphotericin B deoxycholate (Fungizone) for treatment of pulmonary		
522	and Infections, 2019 , 8, 1139-1145 An evaluation of nebulised amphotericin B deoxycholate (Fungizone) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre. <i>Mycoses</i> , 2019 , 62, 1049-1055		6
522 521	An evaluation of nebulised amphotericin B deoxycholate (Fungizone) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre. <i>Mycoses</i> , 2019 , 62, 1049-1055 From culturomics to metagenomics: the mycobiome in chronic respiratory diseases 2019 , 88-118 In vitro and in vivo efficacy of miramistin against drug-resistant fungi. <i>Journal of Medical</i>	5.2	6 5
522 521 520	An evaluation of nebulised amphotericin B deoxycholate (Fungizone) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre. <i>Mycoses</i> , 2019 , 62, 1049-1055 From culturomics to metagenomics: the mycobiome in chronic respiratory diseases 2019 , 88-118 In vitro and in vivo efficacy of miramistin against drug-resistant fungi. <i>Journal of Medical Microbiology</i> , 2019 , 68, 1047-1052	5.2 3.2	658
522 521 520 519	An evaluation of nebulised amphotericin B deoxycholate (Fungizone) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre. <i>Mycoses</i> , 2019 , 62, 1049-1055 From culturomics to metagenomics: the mycobiome in chronic respiratory diseases 2019 , 88-118 In vitro and in vivo efficacy of miramistin against drug-resistant fungi. <i>Journal of Medical Microbiology</i> , 2019 , 68, 1047-1052 The Burden of Fungal Infections in Ethiopia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5, Diagnostic Aspects of Chronic Pulmonary Aspergillosis: Present and New Directions. <i>Current Fungal</i>	5.2 3.2 5.6	6 5 8 14
522 521 520 519 518	An evaluation of nebulised amphotericin B deoxycholate (Fungizone) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre. <i>Mycoses</i> , 2019 , 62, 1049-1055 From culturomics to metagenomics: the mycobiome in chronic respiratory diseases 2019 , 88-118 In vitro and in vivo efficacy of miramistin against drug-resistant fungi. <i>Journal of Medical Microbiology</i> , 2019 , 68, 1047-1052 The Burden of Fungal Infections in Ethiopia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5, Diagnostic Aspects of Chronic Pulmonary Aspergillosis: Present and New Directions. <i>Current Fungal Infection Reports</i> , 2019 , 13, 292-300 The role of medical mycology societies in combating invasive fungal infections in low- and	5.2 3.2 5.6	6 5 8 14 3

514	Chronic pulmonary aspergillosis following pulmonary embolism. <i>Medical Mycology Case Reports</i> , 2019 , 23, 20-22	1.7	3
513	Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. <i>Medical Mycology</i> , 2019 , 57, 133-150	3.9	67
512	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases, The</i> , 2019 , 19, e143-e147	25.5	35
511	Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis. <i>Mycoses</i> , 2019 , 62, 152-156	5.2	8
510	Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma. <i>Clinical Infectious Diseases</i> , 2018 , 67, 156-157	11.6	6
509	Receiver operating characteristic curve analysis of four Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 47-51	2.9	24
508	Corticosteroid treatment is associated with increased filamentous fungal burden in allergic fungal disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 407-414	11.5	55
507	F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis. <i>Journal of Asthma</i> , 2018 , 55, 837-843	1.9	6
506	Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis. <i>PLoS ONE</i> , 2018 , 13, e0193732	3.7	37
505	Global burden of recurrent vulvovaginal candidiasis: a systematic review. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, e339-e347	25.5	161
504	Estimated Burden of Serious Fungal Diseases in Serbia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	7
503	Estimating the Burden of Serious Fungal Infections in Uruguay. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	7
502	Estimated Burden of Serious Fungal Infections in Malawi. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	12
501	Anti-Aspergillus Activities of the Respiratory Epithelium in Health and Disease. <i>Journal of Fungi</i> (Basel, Switzerland), 2018 , 4,	5.6	31
500	The Burden of Fungal Diseases in Romania. Journal of Fungi (Basel, Switzerland), 2018, 4,	5.6	13
499	Burden of Severe Fungal Infections in Burkina Faso. Journal of Fungi (Basel, Switzerland), 2018, 4,	5.6	7
498	Estimation of the Burden of Serious Human Fungal Infections in Malaysia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	9
497	Burden of Fungal Infections in Colombia. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	14

496	The Burden of Serious Fungal Infections in Cameroon. Journal of Fungi (Basel, Switzerland), 2018, 4,	5.6	19
495	Estimated Burden of Serious Fungal Infections in Mozambique. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	15
494	Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. <i>Emerging Infectious Diseases</i> , 2018 , 24,	10.2	50
493	Burden of Serious Fungal Infections in Argentina. Journal of Fungi (Basel, Switzerland), 2018, 4,	5.6	11
492	An Estimate of Severe and Chronic Fungal Diseases in the Republic of Kazakhstan. <i>Journal of Fungi</i> (Basel, Switzerland), 2018 , 4,	5.6	4
491	Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 258-264	14.3	9
490	Mutations in EEA1 are associated with allergic bronchopulmonary aspergillosis and affect phagocytosis of Aspergillus fumigatus by human macrophages. <i>PLoS ONE</i> , 2018 , 13, e0185706	3.7	10
489	Prior subclinical histoplasmosis revealed in Nigeria using histoplasmin skin testing. <i>PLoS ONE</i> , 2018 , 13, e0196224	3.7	10
488	Histoplasmosis in Africa: An emerging or a neglected disease?. <i>PLoS Neglected Tropical Diseases</i> , 2018 , 12, e0006046	4.8	73
487	Burden of fungal infections in Iran. Journal of Infection in Developing Countries, 2018, 12, 910-918	2.3	13
486	A Review of Onychomycosis Due to Aspergillus Species. <i>Mycopathologia</i> , 2018 , 183, 485-493	2.9	35
485	Estimated burden of fungal infections in Italy. <i>Journal of Infection</i> , 2018 , 76, 103-106	18.9	9
484	Acute kidney injury: an unusual complication of posaconazole use. <i>Journal of Chemotherapy</i> , 2018 , 30, 380-383	2.3	3
483	Burden of Serious Fungal Infections in Jordan. Journal of Fungi (Basel, Switzerland), 2018, 4,	5.6	12
482	Lung colonization by Aspergillus fumigatus is controlled by ZNF77. <i>Nature Communications</i> , 2018 , 9, 38	3 5 7.4	27
481	An Estimate of the Burden of Fungal Disease in Norway. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	7
480	Nebulised -Acetylcysteine for Unresponsive Bronchial Obstruction in Allergic Brochopulmonary Aspergillosis: A Case Series and Review of the Literature. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	7
479	Histoplasma capsulatum antigen detection tests as an essential diagnostic tool for patients with advanced HIV disease in low and middle income countries: A systematic review of diagnostic accuracy studies. <i>PLoS Neglected Tropical Diseases</i> , 2018 , 12, e0006802	4.8	37

478	Diagnosis and Management of Pneumocystis Pneumonia in Resource-poor Settings. <i>Journal of Health Care for the Poor and Underserved</i> , 2018 , 29, 107-158	1.4	11
477	Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century. <i>Medical Mycology</i> , 2017 , 55, 691-704	3.9	19
476	Serious fungal infections in Pakistan. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 949-956	5.3	27
475	Serious fungal infections in Chile. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 983-986	5.3	10
474	Burden of fungal infections in Algeria. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 999-1004	5.3	19
473	Serious fungal infections in the Philippines. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 937-941	5.3	11
472	Serious fungal infections in Thailand. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 931-935	5.3	18
471	Serious fungal infections in Peru. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 943-948	5.3	10
470	Serious fungal infections in Egypt. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 971-974	5.3	19
469	Burden of serious fungal infections in Guatemala. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 965-969	5.3	23
468	Serious fungal infections in Korea. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 957-963	5.3	12
467	Burden of serious fungal infections in Bangladesh. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 993-997	5.3	14
466	Serious fungal infections in Canada. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 987-992	5.3	27
465	Predictors of mortality in chronic pulmonary aspergillosis. European Respiratory Journal, 2017, 49,	13.6	64
464	Serious fungal infections in Ecuador. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 975-981	5.3	7
463	Serious fungal diseases in the Republic of Uzbekistan. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 925-929	5.3	7
462	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 873-881	25.5	986
461	World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine. <i>Clinical Infectious Diseases</i> , 2017 , 64, 986-987	11.6	8

(2017-2017)

460	Successful long-term terbinafine therapy in an asthmatic patient with sensitization and bronchiectasis. <i>Medical Mycology Case Reports</i> , 2017 , 16, 31-33	1.7	5
459	The Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. <i>Annals of Emergency Medicine</i> , 2017 , 70, 233-244.e3	2.1	48
458	Identifying rare diseases using electronic medical records: the example of allergic bronchopulmonary aspergillosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 785-791	2.6	9
457	Genetic susceptibility to severe asthma with fungal sensitization. <i>International Journal of Immunogenetics</i> , 2017 , 44, 93-106	2.3	27
456	Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017 , 21, 1056-1061	2.1	33
455	Tuberculosis/cryptococcosis co-infection in China between 1965 and 2016. <i>Emerging Microbes and Infections</i> , 2017 , 6, e73	18.9	27
454	Emergence of Echinocandin Resistance Due to a Point Mutation in the Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	38
453	Aspergillus nodules in chronic granulomatous disease attributable to. <i>Medical Mycology Case Reports</i> , 2017 , 17, 31-33	1.7	5
452	Improvement of fungal disease identification and management: combined health systems and public health approaches. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, e412-e419	25.5	39
451	Pulmonary and sinus fungal diseases in non-immunocompromised patients. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, e357-e366	25.5	54
45°	Recovery from serious fungal infections should be realisable for everyone. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 1111-1113	25.5	21
449	The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach. <i>Current Fungal Infection Reports</i> , 2017 , 11, 242-251	1.4	39
448	Comparative performance of Aspergillus galactomannan ELISA and PCR in sputum from patients with ABPA and CPA. <i>Journal of Microbiological Methods</i> , 2017 , 140, 32-39	2.8	15
447	Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection?. <i>Mycopathologia</i> , 2017 , 182, 1125-1129	2.9	0
446	Opportunistic and Systemic Fungi 2017 , 1681-1709.e3		3
445	Estimating the burden of invasive and serious fungal disease in the United Kingdom. <i>Journal of Infection</i> , 2017 , 74, 60-71	18.9	53
444	Chronic fibrosing pulmonary aspergillosis: a cause of @destroyed lung@yndrome. <i>Infectious Diseases</i> , 2017 , 49, 296-301	3.1	12
443	Aspergillosis and the role of mucins in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017 , 52, 548-555	3.5	21

442	Future Research Priorities in Fungal Resistance. Journal of Infectious Diseases, 2017, 216, S484-S492	7	24
441	Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis. <i>BMC Pulmonary Medicine</i> , 2017 , 17, 149	3.5	15
440	infection in an immunosuppressed patient confined solely to the brain. <i>BMJ Case Reports</i> , 2017 , 2017,	0.9	5
439	Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities. <i>Emerging Infectious Diseases</i> , 2017 , 23, 177-183	10.2	51
438	Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2017 , 3,	5.6	12
437	HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for "Prevention Is Better Than Cure"?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2017 , 3,	5.6	21
436	Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. <i>Journal of Fungi (Basel, Switzerland)</i> , 2017 , 3,	5.6	823
435	Cryptococcal meningitis: A neglected NTD?. PLoS Neglected Tropical Diseases, 2017, 11, e0005575	4.8	33
434	Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis. <i>Journal of Medical Microbiology</i> , 2017 , 66, 898-904	3.2	20
433	An investigation of antifungal stewardship programmes in England. <i>Journal of Medical Microbiology</i> , 2017 , 66, 1581-1589	3.2	24
432	Aspergillus arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases. <i>Medical Mycology</i> , 2017 , 55, 246-254	3.9	16
431	Endogenous Candida endophthalmitis and osteomyelitis associated with CARD9 deficiency. <i>BMJ Case Reports</i> , 2016 , 2016,	0.9	20
430	An estimation of burden of serious fungal infections in France. <i>Journal De Mycologie Medicale</i> , 2016 , 26, 385-390	3	48
429	Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis. <i>BMC Pulmonary Medicine</i> , 2016 , 16, 123	3.5	45
428	Microbial yield from physiotherapy assisted sputum production in respiratory outpatients. <i>BMC Pulmonary Medicine</i> , 2016 , 16, 23	3.5	13
427	Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw055	1	17
426	Electrophilic, Activation-Free Fluorogenic Reagent for Labeling Bioactive Amines. <i>Bioconjugate Chemistry</i> , 2016 , 27, 1430-4	6.3	18
425	Comment on: Antifungal therapy: drug-drug interactions at your fingertips. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2062	5.1	7

(2015-2016)

424	Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). <i>Journal of Infection</i> , 2016 , 72, 240-9	18.9	84
423	Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. <i>European Respiratory Journal</i> , 2016 , 47, 45-68	13.6	396
422	Burden of serious fungal infections in the Dominican Republic. <i>Journal of Infection and Public Health</i> , 2016 , 9, 7-12	7.4	15
421	Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi. <i>PLoS ONE</i> , 2016 , 11, e0158724	3.7	27
420	Estimated burden of fungal infections in Kenya. <i>Journal of Infection in Developing Countries</i> , 2016 , 10, 777-84	2.3	19
419	The burden of serious human fungal infections in Brazil. <i>Mycoses</i> , 2016 , 59, 145-50	5.2	70
418	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 63, e1-e60	11.6	1274
417	Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis. <i>Journal of Infection</i> , 2016 , 73, 485-495	18.9	22
416	Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2016 , 371,	5.8	60
415	Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA). <i>Respiratory Medicine</i> , 2016 , 114, 117-22	4.6	9
414	Global access to antifungal therapy and its variable cost. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3599-3606	5.1	81
413	Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study. <i>Allergy, Asthma and Clinical Immunology</i> , 2016 , 12, 47	3.2	23
412	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 63, 433-42	11.6	216
411	Republished: The clinical spectrum of pulmonary aspergillosis. <i>Postgraduate Medical Journal</i> , 2015 , 91, 403-10	2	30
410	Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). <i>Journal of Asthma</i> , 2015 , 52, 289-95	1.9	33
409	Infectious Disease. How to bolster the antifungal pipeline. <i>Science</i> , 2015 , 347, 1414-6	33.3	303
408	British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. <i>Lancet Infectious Diseases, The</i> , 2015 , 15, 461-74	25.5	117
407	Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. <i>Emerging Infectious Diseases</i> , 2015 , 21, 1041-4	10.2	238

406	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. <i>Drug Resistance Updates</i> , 2015 , 21-22, 30-40	23.2	210
405	Burden of serious fungal infections in Spain. Clinical Microbiology and Infection, 2015, 21, 183-9	9.5	43
404	The clinical spectrum of pulmonary aspergillosis. <i>Thorax</i> , 2015 , 70, 270-7	7.3	410
403	Name changes in medically important fungi and their implications for clinical practice. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 1056-62	9.7	54
402	Response to pneumococcal polysaccharide vaccination in patients with chronic and allergic aspergillosis. <i>Vaccine</i> , 2015 , 33, 7271-7275	4.1	14
401	The burden of fungal disease in Denmark. <i>Mycoses</i> , 2015 , 58 Suppl 5, 15-21	5.2	16
400	Burden of fungal infections in Senegal. <i>Mycoses</i> , 2015 , 58 Suppl 5, 63-9	5.2	22
399	Burden of fungal infections in Qatar. <i>Mycoses</i> , 2015 , 58 Suppl 5, 51-7	5.2	23
398	Burden of serious fungal infections in Belgium. <i>Mycoses</i> , 2015 , 58 Suppl 5, 1-5	5.2	17
397	Burden of serious fungal infections in Tanzania. <i>Mycoses</i> , 2015 , 58 Suppl 5, 70-9	5.2	27
396	Estimated burden of fungal infections in Germany. <i>Mycoses</i> , 2015 , 58 Suppl 5, 22-8	5.2	33
395	Burden of serious fungal infections in Nepal. <i>Mycoses</i> , 2015 , 58 Suppl 5, 45-50	5.2	23
394	Burden of serious fungal infections in Trinidad and Tobago. <i>Mycoses</i> , 2015 , 58 Suppl 5, 80-4	5.2	11
393	Burden of serious fungal infections in Mexico. <i>Mycoses</i> , 2015 , 58 Suppl 5, 34-44	5.2	29
392	Burden of serious fungal infections in Ukraine. <i>Mycoses</i> , 2015 , 58 Suppl 5, 94-100	5.2	14
391	Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens. <i>PLoS ONE</i> , 2015 , 10, e0143165	3.7	19
390	Antibody testing in aspergillosisquo vadis?. <i>Medical Mycology</i> , 2015 , 53, 417-39	3.9	64
389	Burden of serious fungal infections in the Czech Republic. <i>Mycoses</i> , 2015 , 58 Suppl 5, 6-14	5.2	14

388	Burden of serious fungal diseases in Hungary. <i>Mycoses</i> , 2015 , 58 Suppl 5, 29-33	5.2	13
387	Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA. <i>Respiratory Medicine</i> , 2015 , 109, 1509-15	4.6	17
386	Burden of fungal disease in Ireland. <i>Journal of Medical Microbiology</i> , 2015 , 64, 423-426	3.2	24
385	Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 633	5.1	1
384	Elevated levels of the neutrophil chemoattractant pro-platelet basic protein in macrophages from individuals with chronic and allergic aspergillosis. <i>Journal of Infectious Diseases</i> , 2015 , 211, 651-60	7	12
383	Lung microbiome is associated with asthma severity in fungal associated asthma 2015,		4
382	Estimated Burden of Serious Fungal Infections in Jamaica by Literature Review and Modelling. <i>West Indian Medical Journal</i> , 2015 , 64, 245-9		6
381	Estimating the Burden of Fungal Diseases in Israel. Israel Medical Association Journal, 2015, 17, 374-9	0.9	6
380	Long-term stability at -20 °C of Aspergillus galactomannan in serum and bronchoalveolar lavage specimens. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 2108-11	9.7	13
379	Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 1136-1149	25.5	72
378	Reply to "Insufficient demonstration of long-term stability of Aspergillus galactomannan". <i>Journal of Clinical Microbiology</i> , 2014 , 52, 4119	9.7	3
377	Posaconazole responsive cerebral aspergillosis in an immunocompetent adult. <i>Journal of Clinical Neuroscience</i> , 2014 , 21, 1825-7	2.2	8
376	Antifungal resistance: more research needed. <i>Lancet, The</i> , 2014 , 384, 1427	40	15
375	Fungal allergy in asthma-state of the art and research needs. <i>Clinical and Translational Allergy</i> , 2014 , 4, 14	5.2	204
374	Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR. <i>Mycoses</i> , 2014 , 57, 69-78	5.2	58
373	Estimation of the burden of chronic and allergic pulmonary aspergillosis in India. <i>PLoS ONE</i> , 2014 , 9, e1	1 47/ 45	61
372	Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. <i>PLoS ONE</i> , 2014 , 9, e98502	3.7	68
371	Frequency of Pneumocystis jirovecii in sputum from HIV and TB patients in Namibia. <i>Journal of Infection in Developing Countries</i> , 2014 , 8, 349-57	2.3	14

370	Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT. <i>Clinical Microbiology and Infection</i> , 2014 , 20, O960-8	9.5	28
369	A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. <i>Clinical Microbiology and Infection</i> , 2014 , 20, O480-8	9.5	26
368	Occurrence of azole-resistant species of Aspergillus in the UK environment. <i>Journal of Global Antimicrobial Resistance</i> , 2014 , 2, 276-279	3.4	36
367	Clinical implications of interferon-lgenetic and epigenetic variants. <i>Immunology</i> , 2014 , 143, 499-511	7.8	32
366	Environmental fungicides and triazole resistance in Aspergillus. Pest Management Science, 2014, 70, 17	3- ≱6	57
365	Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. <i>Clinical and Experimental Allergy</i> , 2013 , 43, 850-73	4.1	483
364	High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 512-4	5.1	60
363	Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. <i>Clinical Infectious Diseases</i> , 2013 , 57, 828-35	11.6	50
362	Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrencea National Centre® experience. <i>Journal of Cardiothoracic Surgery</i> , 2013 , 8, 180	1.6	72
361	IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. <i>Chest</i> , 2013 , 143, 1351-1357	5.3	63
360	Acute Aspergillus pneumonia associated with mouldy tree bark-chippings, complicated by anti-glomerular basement membrane disease causing permanent renal failure. <i>Medical Mycology Case Reports</i> , 2013 , 2, 125-7	1.7	7
359	Development and evaluation of a calibrator material for nucleic acid-based assays for diagnosing aspergillosis. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2403-5	9.7	21
358	Novel immunologic classification of aspergillosis in adult cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 132, 560-566.e10	11.5	146
357	Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. British Journal of Dermatology, 2013 , 168, 179-85	4	34
356	Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. <i>Mycoses</i> , 2013 , 56, 434-41	5.2	32
355	Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. <i>European Respiratory Journal</i> , 2013 , 41, 621-6	13.6	109
354	The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1486-96	5.1	173
353	Frequency, diagnosis and management of fungal respiratory infections. <i>Current Opinion in Pulmonary Medicine</i> , 2013 , 19, 259-65	3	31

(2011-2013)

352	Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. <i>Clinical Microbiology and Infection</i> , 2013 , 19, E197-204	9.5	67
351	Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum. <i>Thorax</i> , 2013 , 68, 652-7	7.3	56
350	Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. <i>Medical Mycology</i> , 2013 , 51, 361-70	3.9	290
349	Validity and reliability of the St. George@Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. <i>Chest</i> , 2013 , 144, 623-631	5.3	31
348	Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. <i>International Journal of Immunogenetics</i> , 2012 , 39, 224-32	2.3	27
347	Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus. <i>FEMS Microbiology Letters</i> , 2012 , 332, 10-9	2.9	30
346	Hidden killers: human fungal infections. Science Translational Medicine, 2012, 4, 165rv13	17.5	2294
345	Allergic bronchopulmonary mycosis due to Alternaria: Case report and review. <i>Medical Mycology Case Reports</i> , 2012 , 1, 20-3	1.7	10
344	Aspergillus bronchitis without significant immunocompromise. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1272, 73-85	6.5	49
343	Multifocal pulmonary aspergillomas: case series and review. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1272, 58-67	6.5	7
342	Fungi and allergic lower respiratory tract diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 129, 280-91; quiz 292-3	11.5	316
341	Sequencing of mitochondrial genomes of nine Aspergillus and Penicillium species identifies mobile introns and accessory genes as main sources of genome size variability. <i>BMC Genomics</i> , 2012 , 13, 698	4.5	76
340	The performance of real-time PCR, galactomannan, and fungal culture in the diagnosis of invasive aspergillosis in ventilated patients with chronic obstructive pulmonary disease (COPD). <i>Mycopathologia</i> , 2012 , 174, 163-9	2.9	24
339	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 269-89	5.1	316
338	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1304-1304	5.1	4
337	Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. <i>Journal of Asthma</i> , 2012 , 49, 423-33	1.9	99
336	Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapyauthor@response. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 3017-3017	5.1	3
335	Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice. <i>Medical Mycology</i> , 2011 , 49 Suppl 1, S107-13	3.9	94

334	Allergic bronchopulmonary aspergillosis and related allergic syndromes. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011 , 32, 682-92	3.9	59
333	Homogenisation of cystic fibrosis sputum by sonicationan essential step for Aspergillus PCR. <i>Journal of Microbiological Methods</i> , 2011 , 85, 75-81	2.8	40
332	Detection of Aspergillus in lung and other tissue samples using the MycAssay Aspergillus real-time PCR kit. <i>Canadian Journal of Microbiology</i> , 2011 , 57, 765-8	3.2	25
331	Aspergillus fumigatus Bronchopneumonia in a Hellenic Shepherd Dog. <i>Journal of the American Animal Hospital Association</i> , 2011 , 47, e13-8	1.3	16
330	Azole antifungal resistance today: focus on Aspergillus. <i>Current Infectious Disease Reports</i> , 2011 , 13, 48	5-99	38
329	Itraconazole associated quadriparesis and edema: a case report. <i>Journal of Medical Case Reports</i> , 2011 , 5, 140	1.2	6
328	High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. <i>Clinical Infectious Diseases</i> , 2011 , 52, 1123-9	11.6	225
327	Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. <i>Antimicrobial Agents and Chemotherapy</i> ,	5.9	73
326	Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. <i>European Respiratory Journal</i> , 2011 , 37, 865-72	13.6	273
325	Cryptic species and azole resistance in the Aspergillus niger complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 4802-9	5.9	94
324	Peripheral neuropathy in patients on long-term triazole antifungal therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2136-9	5.1	48
323	A public resource for metabolic pathway mapping of Aspergillus fumigatus Af293. <i>Medical Mycology</i> , 2011 , 49 Suppl 1, S114-9	3.9	8
322	Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. <i>Thorax</i> , 2011 , 66, 638-40	7.3	43
321	Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. <i>Bulletin of the World Health Organization</i> , 2011 , 89, 864-72	8.2	227
320	Too many mouldy joints - marijuana and chronic pulmonary aspergillosis. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011 , 3, e2011005	3.2	39
319	Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 1872-8	9.7	74
318	Mixed mould species in laboratory cultures of respiratory specimens: how should they be reported, and what are the indications for susceptibility testing?. <i>Journal of Clinical Pathology</i> , 2011 , 64, 543-5	3.9	7
317	Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. <i>Clinical Microbiology and Infection</i> , 2010 , 16, 683-8	9.5	57

(2009-2010)

316	Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation.	9.7	69
315	Journal of Clinical Microbiology, 2010 , 48, 2043-6 Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clinical Infectious Diseases, 2010 , 51, 1383-91	11.6	105
314	Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2116-8	5.1	230
313	A 27-year-old woman with acute, severe asthma who developed respiratory failure. <i>Chest</i> , 2010 , 137, 724-7	5.3	
312	Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. <i>International Journal of</i>	14.3	30
311	Antimicrobial Agents, 2010 , 35, 146-51 Tremor: a newly described adverse event with long-term itraconazole therapy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 327-9	5.5	15
310	Aspergillus DNA contamination in blood collection tubes. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010 , 67, 392-4	2.9	46
309	Therapy for fungal diseases: opportunities and priorities. <i>Trends in Microbiology</i> , 2010 , 18, 195-204	12.4	225
308	Genetic variability of innate immunity impacts human susceptibility to fungal diseases. <i>International Journal of Infectious Diseases</i> , 2010 , 14, e460-8	10.5	37
307	Candida tropicalis in human disease. <i>Critical Reviews in Microbiology</i> , 2010 , 36, 282-98	7.8	71
306	Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2010 , 29, 1387-9.	4 ^{5.3}	31
305	A study on Aspergillus species in houses of asthmatic patients from Sari City, Iran and a brief review of the health effects of exposure to indoor Aspergillus. <i>Environmental Monitoring and Assessment</i> , 2010 , 168, 481-7	3.1	40
304	Aspergillus fumigatus allergen expression is coordinately regulated in response to hydrogen peroxide and cyclic AMP. <i>Clinical and Molecular Allergy</i> , 2010 , 8, 15	3.7	5
303	Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. <i>Emerging Infectious Diseases</i> , 2009 , 15, 1068-76	10.2	594
302	Using aCGH to study intraspecific genetic variability in two pathogenic molds, Aspergillus fumigatus and Aspergillus flavus. <i>Medical Mycology</i> , 2009 , 47 Suppl 1, S34-41	3.9	13
301	In vitro susceptibility of non-Aspergillus allergenic fungal species to azoles. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 834-6	5.1	2
300	Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 3453-61	5.9	72
299	Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 11-8	10.2	275

298	Aspergillus genomes and the Aspergillus cloud. <i>Nucleic Acids Research</i> , 2009 , 37, D509-14	20.1	16
297	Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. <i>Clinical Infectious Diseases</i> , 2009 , 49, 928-30	11.6	91
296	Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope, 2009 , 119, 1809-18	3.6	294
295	Aflatoxin and ochratoxin production by Aspergillus species under ex vivo conditions. <i>Mycopathologia</i> , 2009 , 168, 185-91	2.9	12
294	Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. <i>Clinical and Experimental Allergy</i> , 2009 , 39, 1677-83	4.1	127
293	Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. <i>Clinical and Experimental Immunology</i> , 2009 , 156, 40-51	6.2	20
292	The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis. <i>Respirology</i> , 2009 , 14, 1121-7	3.6	54
291	Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2009 , 11, 89-93	2.7	89
290	Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. <i>Journal of Infection</i> , 2009 , 58, 145-53	18.9	27
289	Excess mortality, length of stay and cost attributable to candidaemia. <i>Journal of Infection</i> , 2009 , 59, 360	-5 8.9	61
288	Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. <i>Drug Resistance Updates</i> , 2009 , 12, 141-7	23.2	201
287	Isolation, identification and susceptibility of Pyrenochaeta romeroi in a case of eumycetoma of the foot in the UK. <i>International Journal of Antimicrobial Agents</i> , 2009 , 34, 617-8	14.3	19
286	Invasive pulmonary aspergillosis 10 years post bone marrow transplantation: a case report. <i>Journal of Medical Case Reports</i> , 2009 , 3, 26	1.2	2
285	Does Itraconazole Improve Quality of Life in Severe Asthma with Fungal Sensitization?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 192-192	10.2	2
284	Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 161-6	5.1	53
283	EUCAST technical note on fluconazole. Clinical Microbiology and Infection, 2008, 14, 193-5	9.5	80
282	EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. <i>Clinical Microbiology and Infection</i> , 2008 , 14, 398-405	9.5	348
281	EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. <i>Clinical Microbiology and Infection</i> , 2008 , 14, 982-4	9.5	282

280	EUCAST Technical Note on voriconazole. Clinical Microbiology and Infection, 2008, 14, 985-7	9.5	47
279	Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED. <i>Clinical and Experimental Immunology</i> , 2008 , 154, 406-14	6.2	44
278	A case of spotted fever group rickettsiosis imported into the United Kingdom and treated with ciprofloxacin: a case report. <i>Journal of Medical Case Reports</i> , 2008 , 2, 98	1.2	2
277	An aspergilloma caused by Aspergillus flavus. <i>Medical Mycology</i> , 2008 , 46, 275-8	3.9	2 0
276	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical	11.6	3744
275	Infectious Diseases, 2008, 46, 1813-21 Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2008, 46, 327-60	11.6	2097
274	Voriconazole plasma monitoring. Archives of Disease in Childhood, 2008, 93, 578-81	2.2	34
273	New and emerging treatments for fungal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61 Suppl 1, i19-30	5.1	138
272	Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus. <i>PLoS Genetics</i> , 2008 , 4, e1000046	6	382
271	Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. <i>Journal of Infectious Diseases</i> , 2008 , 197, 618-21	7	195
270	Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 4389-97	5.6	149
269	Chronic mucocutaneous candidiasis and oesophageal cancer. <i>Medical Mycology</i> , 2008 , 46, 85-91	3.9	40
268	Therapeutic drug monitoring for triazoles. Current Opinion in Infectious Diseases, 2008, 21, 580-6	5.4	106
267	Genomic analysis of allergen genes in Aspergillus spp: the relevance of genomics to everyday research. <i>Medical Mycology</i> , 2007 , 45, 17-26	3.9	39
266	Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30, 93-4	14.3	36
265	Aspergillus flavus: human pathogen, allergen and mycotoxin producer. <i>Microbiology (United Kingdom)</i> , 2007 , 153, 1677-1692	2.9	563
264	R⊠istance dʿl Aspergillus fumigatus l'plusieurs dEiv⊠ azol⊠. <i>Journal De Mycologie Medicale</i> , 2007 , 17, S11-S15	3	
263	Flucytosine therapeutic monitoring: 15 years experience from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 791-3	5.1	54

262	Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). <i>Journal of Clinical Microbiology</i> , 2007 , 45, 109-11	9.7	43
261	Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3760-2	5.9	20
260	Does one voriconazole breakpoint suit all Candida species?. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 2093; author reply 2094	9.7	6
259	Reply to Verweij et al. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1667-1668	11.6	3
258	Comparison of 2 studies of treatment of invasive aspergillosis. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1106-8; author reply 1108-10	11.6	12
257	Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007 , 45, 183-6	5.9	82
256	Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 285-95	5.9	34
255	A cautionary tale: Lack of consistency in allele sizes between two laboratories for a published multilocus microsatellite typing system. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 522-8	9.7	71
254	What can comparative genomics tell us about species concepts in the genus Aspergillus?. <i>Studies in Mycology</i> , 2007 , 59, 11-7	22.2	70
253	Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. <i>Clinical Infectious Diseases</i> , 2007 , 44, 373-9	11.6	452
253252			45 ²
	Clinical Infectious Diseases, 2007 , 44, 373-9		
252	Cytokine profiling of pulmonary aspergillosis. <i>International Journal of Immunogenetics</i> , 2006 , 33, 297-3 Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely	02.3	68
252 251	Cytokine profiling of pulmonary aspergillosis. <i>International Journal of Immunogenetics</i> , 2006 , 33, 297-3 Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. <i>BMC Genomics</i> , 2006 , 7, 251	02.3 4.5 3.9	68 54
252 251 250	Cytokine profiling of pulmonary aspergillosis. <i>International Journal of Immunogenetics</i> , 2006 , 33, 297-3. Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. <i>BMC Genomics</i> , 2006 , 7, 251 Aspergillus and aspergillosis-Progress on many fronts. <i>Medical Mycology</i> , 2006 , 44, S1	02.3 4.5 3.9	68 54 11
252251250249	Cytokine profiling of pulmonary aspergillosis. <i>International Journal of Immunogenetics</i> , 2006 , 33, 297-3. Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. <i>BMC Genomics</i> , 2006 , 7, 251 Aspergillus and aspergillosis-Progress on many fronts. <i>Medical Mycology</i> , 2006 , 44, S1 Relative reactivity of Aspergillus allergens used in serological tests. <i>Medical Mycology</i> , 2006 , 44, S23-S2 Audit of laboratory mycology services for the management of patients with fungal infections in the	022.3 4.5 3.9 2.83.9	68 54 11
252251250249248	Cytokine profiling of pulmonary aspergillosis. <i>International Journal of Immunogenetics</i> , 2006 , 33, 297-3 Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. <i>BMC Genomics</i> , 2006 , 7, 251 Aspergillus and aspergillosis-Progress on many fronts. <i>Medical Mycology</i> , 2006 , 44, S1 Relative reactivity of Aspergillus allergens used in serological tests. <i>Medical Mycology</i> , 2006 , 44, S23-S2 Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England. <i>Journal of Clinical Pathology</i> , 2006 , 59, 759-63 In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble	02.3 4.5 3.9 2.83.9	68 54 11 16 4

(2005-2006)

244	Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 3680-8	5.9	33
243	Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings. <i>Scandinavian Journal of Infectious Diseases</i> , 2006 , 38, 945-9		21
242	Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 1198-207	5.1	70
241	Sub-cutaneous phaeohyphomycosis caused by Cladophialophora devriesii in a United Kingdom resident. <i>Medical Mycology</i> , 2006 , 44, 553-6	3.9	7
240	Multi-azole resistance in Aspergillus fumigatus. <i>International Journal of Antimicrobial Agents</i> , 2006 , 28, 450-3	14.3	164
239	Whole genome comparison of the A. fumigatus family. <i>Medical Mycology</i> , 2006 , 44, S3-S7	3.9	41
238	The link between fungi and severe asthma: a summary of the evidence. <i>European Respiratory Journal</i> , 2006 , 27, 615-26	13.6	592
237	Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. <i>American Journal of Medicine</i> , 2006 , 119, 527.e17-24	2.4	81
236	Fungal contamination of bedding. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006 , 61, 140-2	9.3	52
235	Comparison of two fluorescent whiteners, Calcofluor and Blankophor, for the detection of fungal elements in clinical specimens in the diagnostic laboratory. <i>Clinical Microbiology and Infection</i> , 2006 , 12, 181-4	9.5	39
234	Post-operative aspergillosis. Clinical Microbiology and Infection, 2006, 12, 1060-76	9.5	109
233	The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. <i>Journal of Infection</i> , 2006 , 52, e133-7	18.9	64
232	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. <i>Journal of Infection</i> , 2006 , 53, 337-49	18.9	256
231	Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. <i>Medical Mycology</i> , 2006 , 44, S319-S325	3.9	51
230	Laboratory diagnosis of invasive aspergillosis. Lancet Infectious Diseases, The, 2005, 5, 609-22	25.5	378
229	Correlation between in vitro growth rate and in vivo virulence in Aspergillus fumigatus. <i>Medical Mycology</i> , 2005 , 43, 397-401	3.9	46
228	Evidence for recombination in Candida glabrata. Fungal Genetics and Biology, 2005, 42, 233-43	3.9	50
227	What the Aspergillus genomes have told us. <i>Medical Mycology</i> , 2005 , 43 Suppl 1, S3-5	3.9	28

226	Genome sequencing and analysis of Aspergillus oryzae. <i>Nature</i> , 2005 , 438, 1157-61	50.4	962
225	Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. <i>Nature</i> , 2005 , 438, 1151-6	50.4	1114
224	Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. <i>Nature</i> , 2005 , 438, 1105-15	50.4	1094
223	Evidence for sexuality in the opportunistic fungal pathogen Aspergillus fumigatus. <i>Current Biology</i> , 2005 , 15, 1242-8	6.3	253
222	Genomics of Aspergillus fumigatus. Revista Iberoamericana De Micologia, 2005, 22, 223-8	1.6	34
221	Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005 , 24, 628-33	5.3	18
220	Book Review M.A. Klich, Identification of Common Aspergillus Species, ASM Press, Washington, DC, 2002, 116 pp., \$39.95 <i>Mycopathologia</i> , 2005 , 159, 89-89	2.9	
219	Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. <i>BMC Pulmonary Medicine</i> , 2005 , 5, 4	3.5	156
218	Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1448-52	11.6	94
217	Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 590-3	5.1	31
216	Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. <i>Journal of Infectious Diseases</i> , 2005 , 192, 673-80	7	18
215	The invasive and saprophytic syndromes due to Aspergillus spp. <i>Medical Mycology</i> , 2005 , 43 Suppl 1, S20	07:38	166
214	Aspergillosis in "nonimmunocompromised" critically ill patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 170, 580-1	10.2	27
213	Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1563-71	11.6	538
212	Molecular mechanisms of primary resistance to flucytosine in Candida albicans. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4377-86	5.9	109
211	Adverse reactions to voriconazole. Clinical Infectious Diseases, 2004, 39, 1241-4	11.6	157
210	Mycobacterium chelonae finger infection associated with Raynaud® phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1178-9	2.4	2
209	Inactivation of transcription factor gene ACE2 in the fungal pathogen Candida glabrata results in hypervirulence. <i>Eukaryotic Cell</i> , 2004 , 3, 546-52		62

208	Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 53, 743-9	5.1	35
207	Optimising antifungal therapy for individual patients. <i>Internal Medicine Journal</i> , 2004 , 34, 147-9	1.6	5
206	Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist. European Radiology, 2004, 14, 2030-7	78	9
205	Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. <i>Journal of Infection</i> , 2004 , 49, 136-40	18.9	5
204	Comparison of extracellular phospholipase activities in clinical and environmental Aspergillus fumigatus isolates. <i>Medical Mycology</i> , 2004 , 42, 81-6	3.9	30
203	Insight into the genome of Aspergillus fumigatus: analysis of a 922 kb region encompassing the nitrate assimilation gene cluster. <i>Fungal Genetics and Biology</i> , 2004 , 41, 443-53	3.9	50
202	Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 650-7	3.2	56
201	Interactions of human phagocytes with moulds Fusarium spp. and Verticillium nigrescens possessing different pathogenicity. <i>Medical Mycology</i> , 2003 , 41, 503-9	3.9	10
200	Allergic bronchopulmonary aspergillosis in cystic fibrosisstate of the art: Cystic Fibrosis Foundation Consensus Conference. <i>Clinical Infectious Diseases</i> , 2003 , 37 Suppl 3, S225-64	11.6	506
199	Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 297-304	5.1	6
198	In vitro susceptibilities of zygomycetes to conventional and new antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 45-52	5.1	246
197	Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed		
	nomenclature change, and review. <i>Clinical Infectious Diseases</i> , 2003 , 37 Suppl 3, S265-80	11.6	357
196		11.6	357 146
196 195	nomenclature change, and review. <i>Clinical Infectious Diseases</i> , 2003 , 37 Suppl 3, S265-80 Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. <i>Clinical Infectious Diseases</i> ,		
	nomenclature change, and review. <i>Clinical Infectious Diseases</i> , 2003 , 37 Suppl 3, S265-80 Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. <i>Clinical Infectious Diseases</i> , 2003 , 37 Suppl 3, S188-224 Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole.	11.6	146
195	nomenclature change, and review. <i>Clinical Infectious Diseases</i> , 2003 , 37 Suppl 3, S265-80 Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. <i>Clinical Infectious Diseases</i> , 2003 , 37 Suppl 3, S188-224 Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003 , 22, 681-5 Candida glabrata STE12 is required for wild-type levels of virulence and nitrogen starvation induced	11.6 5.3	146
195	Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. <i>Clinical Infectious Diseases</i> , 2003, 37 Suppl 3, S188-224 Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003, 22, 681-5 Candida glabrata STE12 is required for wild-type levels of virulence and nitrogen starvation induced filamentation. <i>Molecular Microbiology</i> , 2003, 50, 1309-18	11.65.34.1	146 13 58

190	Echinocandin antifungal drugs. Lancet, The, 2003, 362, 1142-51	40	835
189	British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. <i>Lancet Infectious Diseases, The</i> , 2003 , 3, 230-40	25.5	158
188	Standards of care for invasive fungal infections (Authors Oreply. <i>Lancet Infectious Diseases, The</i> , 2003 , 3, 402-403	25.5	
187	Advances against aspergillosis. <i>Clinical Infectious Diseases</i> , 2003 , 37 Suppl 3, S155-6	11.6	17
186	Multilocus sequence typing of Candida glabrata reveals geographically enriched clades. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 5709-17	9.7	143
185	Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 5236-7	9.7	62
184	Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. <i>Laboratory Animals</i> , 2003 , 37, 126-31	2.6	56
183	Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 913-9	5.1	62
182	Cutaneous childhood sarcoidosisa rare disease refractory to treatment. <i>British Journal of Rheumatology</i> , 2003 , 42, 1570-1		3
181	Invasive infection due to penicillium species other than P. marneffei. <i>Journal of Infection</i> , 2002 , 45, 184-	95 8.9	85
180	Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 2876-85	9.7	49
179	Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. <i>Clinical Infectious Diseases</i> , 2002 , 34, 563-71	11.6	699
178	In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3323-6	5.9	38
177	In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 62-8	5.9	205
176	In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 50, 189-94	5.1	54
175	In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 2708-11	5.9	69
174	Azole cross-resistance in Aspergillus fumigatus. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 556-7	7 5.9	104
173	In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 50, 1071-4	5.1	31

(2001-2002)

172	Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1953-9	5.9	47
171	Echinocandins: a new class of antifungal. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 49, 889-91	5.1	199
170	Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. <i>Clinical Infectious Diseases</i> , 2002 , 34, 7-14	11.6	2009
169	Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. <i>New England Journal of Medicine</i> , 2002 , 347, 408-15	59.2	2596
168	Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. <i>Fungal Genetics and Biology</i> , 2002 , 36, 199-20	0 <i>∂</i> ^{.9}	159
167	Sequencing the Aspergillus fumigatus genome. Lancet Infectious Diseases, The, 2002, 2, 251-3	25.5	75
166	Aspergillosis. Pathogenesis, clinical manifestations, and therapy. <i>Infectious Disease Clinics of North America</i> , 2002 , 16, 875-94, vi	6.5	253
165	Termination of development of D0870. Journal of Antimicrobial Chemotherapy, 2001, 47, 720-1	5.1	9
164	Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 648-53	1.8	107
163	Fungal infection of the diabetic foot: two distinct syndromes. <i>Diabetic Medicine</i> , 2001 , 18, 567-72	3.5	25
162	Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. Journal of Clinical Microbiology, 2001 , 39, 2458-62	9.7	30
161	Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. <i>Journal of Infectious Diseases</i> , 2001 , 184, 653-6	7	132
160	A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 789-97	1.6	51
159	In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 1882-5	5.9	46
158	Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 1456-62	5.9	49
157	Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. <i>Clinical Infectious Diseases</i> , 2001 , 33, 95-106	11.6	51
156	Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. <i>Journal of Antimicrobial Chemotherapy</i> , 2001 , 48, 583-6	5.1	19
155	Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 253-9	2.2	469

154	Antifungal drug resistance in Aspergillus. Journal of Infection, 2000, 41, 203-20	18.9	124
153	Candida glabrata oesophagitis in a patient without HIV infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2000 , 19, 561-2	5.3	7
152	In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 2664-71	5.9	18
151	Invasive aspergillosis in a patient with MELAS syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 68, 765-7	5.5	6
150	Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2000 , 45, 85-93	5.1	77
149	Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2000 , 30, 696-709	11.6	641
148	In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 441-3	5.9	59
147	Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe FranBis du Mylome. Clinical Infectious Diseases,	11.6	48
146	Early diagnosis of invasive aspergillosis. <i>Lancet, The</i> , 2000 , 355, 2076	40	
145	Molecular genetics in Aspergillus fumigatus. Current Opinion in Microbiology, 2000, 3, 468-74	7.9	72
144	Early diagnosis of invasive aspergillosis. <i>Lancet, The</i> , 2000 , 355, 423-4	40	52
143	Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia. <i>Pediatric Hematology and Oncology</i> , 2000 , 17, 497-504	1.7	21
142	Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B. <i>Antimicrobial Agents and</i>	5.9	46
141	Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 1264-6	5.9	51
140	Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 44, 577-8	5.1	9
139	Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870. <i>Clinical Infectious Diseases</i> , 1999 , 28, 587-96	11.6	5
138	Endemic mycoses: a treatment update. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 43, 321-31	5.1	90
137	Aspergillus fumigatus catalases: cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases. <i>FEMS Immunology and Medical Microbiology</i> , 1999 , 23, 125-33		24

136	Cryptococcal meningitis in the immunocompromised host: intracranial hypertension and other complications. <i>Mycopathologia</i> , 1999 , 146, 1-8	2.9	20
135	Use of the 6-methylsalicylic-acid-synthase gene as a discriminating marker between Aspergillus terreus and Aspergillus flavipes. <i>Folia Microbiologica</i> , 1999 , 44, 503-9	2.8	5
134	Molecular typing of Aspergillus terreus by random amplification of polymorphic DNA. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999 , 18, 838-41	5.3	14
133	Invasive yeast infections other than Candida spp. in acute leukaemia. <i>Journal of Hospital Infection</i> , 1999 , 41, 181-94	6.9	93
132	Activity of pradimicin BMS-181184 against Aspergillus spp. <i>International Journal of Antimicrobial Agents</i> , 1999 , 12, 267-9	14.3	7
131	An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. <i>Journal of Infection</i> , 1998 , 37, 173-80	18.9	214
130	Variation in morphotype, karyotype and DNA type of fluconazole resistant Candida albicans from an AIDS patient. <i>Journal of Infection</i> , 1998 , 36, 57-62	18.9	11
129	The treatment of oropharyngeal candidiasis in HIV-infected patients with oral amphotericin B suspension. <i>AIDS Patient Care and STDs</i> , 1998 , 12, 625-7	5.8	7
128	In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 91-4	5.1	48
127	Invasive aspergillosis. Clinical Infectious Diseases, 1998, 26, 781-803; quiz 804-5	11.6	1363
127 126	Invasive aspergillosis. <i>Clinical Infectious Diseases</i> , 1998 , 26, 781-803; quiz 804-5 In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 389-92		1363 66
	In-vitro activities of amphotericin B. itraconazole and voriconazole against 150 clinical and		
126	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 389-92 Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole	5.1	66
126	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 389-92 Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. <i>Aids</i> , 1998 , 12, 411-6	5.1 3.5 1.8	66
126 125 124	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 389-92 Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. <i>Aids</i> , 1998 , 12, 411-6 Skull base osteitis following fungal sinusitis. <i>Journal of Laryngology and Otology</i> , 1998 , 112, 92-7 In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole	5.1 3.5 1.8	66 9 35
126 125 124	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 389-92 Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. <i>Aids</i> , 1998 , 12, 411-6 Skull base osteitis following fungal sinusitis. <i>Journal of Laryngology and Otology</i> , 1998 , 112, 92-7 In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 2726-30 Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a	5.1 3.5 1.8	66 9 35 71
126 125 124 123	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 389-92 Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. <i>Aids</i> , 1998 , 12, 411-6 Skull base osteitis following fungal sinusitis. <i>Journal of Laryngology and Otology</i> , 1998 , 112, 92-7 In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 2726-30 Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 873-8 Polar lipids of Aspergillus fumigatus, A. niger, A. nidulans, A. flavus and A. terreus. <i>Medical Mycology</i>	5.1 3.5 1.8 5.9	66 9 35 71

118	Echinocandins and pneumocandins—a new antifungal class with a novel mode of action. <i>Journal of Antimicrobial Chemotherapy</i> , 1997 , 40, 611-4	5.1	99
117	Amphotericin B resistance testing of Candida spp.: a comparison of methods. <i>Journal of Antimicrobial Chemotherapy</i> , 1997 , 40, 109-12	5.1	36
116	Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1997 , 40, 779-88	5.1	15
115	A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. <i>Aids</i> , 1997 , 11, 759-63	3.5	7
114	Prevalence of phthioic acid in Aspergillus species. <i>Medical Mycology</i> , 1997 , 35, 143-145	3.9	4
113	Inhibition and interaction of cytochrome P450 of Candida kruseiwith azole antifungal drugs. <i>Medical Mycology</i> , 1997 , 35, 19-25	3.9	25
112	Neurospora sitophila pulmonary infection in a patient with AIDS. <i>AIDS Patient Care and STDs</i> , 1997 , 11, 223-6	5.8	1
111	In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei. <i>Journal of Antimicrobial Chemotherapy</i> , 1997 , 39, 731-6	5.1	3
110	The challenge of invasive aspergillosis: Increasing numbers in diverse patient groups. <i>International Journal of Infectious Diseases</i> , 1997 , 2, 61-63	10.5	14
109	Itraconazole resistance in Aspergillus fumigatus. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 136	4 5 89	397
109	Itraconazole resistance in Aspergillus fumigatus. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 136 Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 2310-1	4 5 89 5.9	397
	Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.		
108	Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrobial Agents and Chemotherapy, 1997, 41, 2310-1 In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole	5.9	48
108	Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrobial Agents and Chemotherapy, 1997, 41, 2310-1 In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrobial Agents and Chemotherapy, 1997, 41, 1124-6 Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.	5.9 5.9	48
108 107 106	Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 2310-1 In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 1124-6 Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 1504-7 Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. <i>European Journal of Clinical</i>	5.9 5.9 5.9	48 87 98
108 107 106	Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 2310-1 In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 1124-6 Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 1504-7 Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997 , 16, 424-36 Species differentiation by internally transcribed spacer PCR and Hhal digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. <i>Journal</i>	5.9 5.9 5.9	48 87 98 125
108 107 106 105	Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 2310-1 In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 1124-6 Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 1504-7 Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997 , 16, 424-36 Species differentiation by internally transcribed spacer PCR and Hhal digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. <i>Journal of Clinical Microbiology</i> , 1997 , 35, 1036-9 High incidence of antifungal drug resistance in Candida tropicalis. <i>International Journal of</i>	5.9 5.9 5.9 5.3	48 87 98 125 21

100	Hyperbaric oxygen therapy in a woman who declined colostomy. Lancet, The, 1996, 348, 197	40	7
99	Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. <i>Antimicrobial Agents and Chemotherapy</i> , 1996 , 40, 1382-6	5.9	20
98	Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 1996 , 40, 2443-6	5.9	52
97	In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1996 , 40, 2229-31	5.9	11
96	Rapid genotyping of Escherichia coli O157 isolates by random amplification of polymorphic DNA. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996 , 15, 297-302	5.3	21
95	Acute meningo-encephalitis in pregnancy-a problem of differential diagnosis. <i>European Journal of Neurology</i> , 1996 , 3, 267-71	6	
94	Aspergillus wound infection following laparostomy. <i>Journal of Infection</i> , 1996 , 33, 119-21	18.9	16
93	Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases, 1996, 23, 608-15	11.6	593
92	Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. <i>Infection and Immunity</i> , 1996 , 64, 751-5	3.7	62
91	D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis. <i>Journal of Clinical Microbiology</i> , 1996 , 34, 218-21	9.7	26
90	Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. <i>Journal of Clinical Microbiology</i> , 1996 , 34, 87-93	9.7	66
89	Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. <i>Journal of Infection</i> , 1995 , 30, 153-5	18.9	32
88	Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. <i>FEMS Microbiology Letters</i> , 1995 , 131, 337-41	2.9	62
87	Anti-Cryptococcus neoformans antibodies during cryptococcosis in patients with the acquired immunodeficiency syndrome. <i>Serodiagnosis and Immunotherapy in Infectious Disease</i> , 1995 , 7, 181-188		9
86	In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. <i>Antimicrobial Agents and Chemotherapy</i> , 1995 , 39, 868-71	5.9	35
85	Antifungal drug susceptibility testing. Working Party of the British Society for Antimicrobial chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1995 , 36, 899-909	5.1	15
84	Efficacy of oral saperconazole in systemic murine aspergillosis. <i>Medical Mycology</i> , 1995 , 33, 311-7	3.9	32
83	Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 1995 , 39, 1809-14	5.9	35

82	Aspergillus fungemia: report of two cases and review. Clinical Infectious Diseases, 1995, 20, 598-605	11.6	135
81	Commentary: unusual manifestations of aspergillosis. <i>Thorax</i> , 1995 , 50, 812-3	7.3	56
80	Uncommon invasive mycoses in AIDS. <i>Aids</i> , 1995 , 9, 411-420	3.5	27
79	DNA typing of epidemiologically-related isolates of Aspergillus fumigatus. <i>Epidemiology and Infection</i> , 1995 , 114, 161-8	4.3	22
78	Aflatoxin and outcome from acute lower respiratory infection in children in The Philippines. <i>Annals of Tropical Paediatrics</i> , 1995 , 15, 209-16		12
77	High prevalence of antifungal resistance in Candida spp. from patients with AIDS. <i>Journal of Antimicrobial Chemotherapy</i> , 1994 , 34, 659-68	5.1	121
76	Invasive aspergillosis in patients with AIDS. <i>Clinical Infectious Diseases</i> , 1994 , 19 Suppl 1, S41-8	11.6	87
75	Administering amphotericin Ba practical approach. <i>Journal of Antimicrobial Chemotherapy</i> , 1994 , 33, 203-13	5.1	97
74	Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. <i>Antimicrobial Agents and Chemotherapy</i> , 1994 , 38, 1561-6	5.9	51
73	Aspergillus tracheobronchitis. <i>Clinical Infectious Diseases</i> , 1994 , 19, 1176-7	11.6	7
72	Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples. <i>Journal of Medical Microbiology</i> , 1994 , 40, 241-5	3.2	7
71	Oxygen requirements of Aspergillus species. <i>Journal of Medical Microbiology</i> , 1994 , 41, 311-5	3.2	52
70	Successful treatment of sinusitis caused by Cunninghamella bertholletiae. <i>Clinical Infectious Diseases</i> , 1994 , 19, 313-6	11.6	38
69	Reply to Troke and Hitchcock@letter. <i>Journal of Infection</i> , 1994 , 28, 225-227	18.9	1
68			4.5
	Treatment of invasive aspergillosis. <i>Journal of Infection</i> , 1994 , 28 Suppl 1, 25-33	18.9	45
67	Treatment of invasive aspergillosis. <i>Journal of Infection</i> , 1994 , 28 Suppl 1, 25-33 Early management of community-acquired pneumonia [correction of asthma]. <i>Respiratory Medicine</i> , 1994 , 88, 73-4	18.9 4.6	45
6 ₇	Early management of community-acquired pneumonia [correction of asthma]. Respiratory Medicine,		412

64	Evolving Etiology of Fungal Infection in the 1990s. Infectious Diseases in Clinical Practice, 1994, 3, S50-S	550.2	4
63	Fluconazole-resistant candidosis in an HIV cohort. <i>Aids</i> , 1994 , 8, 787-92	3.5	93
62	Temperature-dependent expression of elastase in Aspergillus species. <i>Medical Mycology</i> , 1993 , 31, 455-	4 5 ,89	8
61	Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. <i>Thorax</i> , 1993 , 48, 1285-7	7.3	18
60	In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. <i>Journal of Antimicrobial Chemotherapy</i> , 1993 , 32, 831-6	5.1	21
59	Empiric amphotericin B therapy: the need for a reappraisal. <i>Blood Reviews</i> , 1993 , 7, 208-14	11.1	17
58	Fluconazole resistance in Candida in patients with AIDSa therapeutic approach. <i>Journal of Infection</i> , 1993 , 26, 117-25	18.9	76
57	Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. <i>Clinical Infectious Diseases</i> , 1992 , 14, 165-74	11.6	182
56	Quantitative preservation of viability of Aspergillus fumigatus. <i>Medical Mycology</i> , 1992 , 30, 485-8	3.9	14
55	Time to finish with "AIDS"?. <i>Lancet, The</i> , 1992 , 339, 1298	40	1
54	In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 1992 , 15, 21-34	2.9	119
53	Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient. <i>Journal of Infection</i> , 1992 , 24, 73-9	18.9	16
52	Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. <i>Journal of Infection</i> , 1992 , 24, 212-3	18.9	4
51	Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis. <i>Infection and Immunity</i> , 1992 , 60, 5153-6	3.7	33
50	Pulmonary aspergillosis in the acquired immunodeficiency syndrome. <i>New England Journal of Medicine</i> , 1991 , 324, 654-62	59.2	420
49	Neisseria lactamica meningitis following skull trauma. <i>Clinical Infectious Diseases</i> , 1991 , 13, 216-8	11.6	28
48	Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 1991 , 35, 1329-33	5.9	69
47	Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. <i>The American Review of Respiratory Disease</i> , 1991 , 144, 552-6		221

46	Endocarditis due to Trichosporon beigelii: in vitro susceptibility of isolates and review. <i>Clinical Infectious Diseases</i> , 1991 , 13, 383-6	11.6	26
45	Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. <i>Chest</i> , 1991 , 100, 813-	9 5.3	181
44	Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. <i>American Journal of Medicine</i> , 1991 , 91, 267-72	2.4	195
43	The treatment of invasive aspergillosis. <i>Infectious Diseases Newsletter (New York, N Y)</i> , 1991 , 10, 65-69		1
42	Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. <i>Journal of Clinical Microbiology</i> , 1991 , 29, 333-9	9.7	52
41	Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. Journal of Antimicrobial Chemotherapy, 1991 , 28 Suppl B, 1-16	5.1	75
40	Cyclosporine and itraconazole interaction in heart and lung transplant recipients. <i>Annals of Internal Medicine</i> , 1990 , 113, 327-9	8	111
39	In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1990 , 9, 693-7	5.3	16
38	Itraconazole therapy for chronic coccidioidal meningitis. <i>Annals of Internal Medicine</i> , 1990 , 112, 108-12	8	105
37	Treatment of coccidioidal meningitis with fluconazole. <i>Clinical Infectious Diseases</i> , 1990 , 12 Suppl 3, S38	0⊦9 .6	64
36	The relationship between @ormalOfluid retention in women and idiopathic oedema. <i>Postgraduate Medical Journal</i> , 1990 , 66, 363-6	2	9
35	Transplacental transfer of aflatoxin in humans. <i>Carcinogenesis</i> , 1990 , 11, 1033-5	4.6	77
34	High serum concentrations of aflatoxin in Nepal as measured by enzyme-linked immunosorbent serum assay. <i>Human and Experimental Toxicology</i> , 1990 , 9, 143-6	3.4	4
33	Adverse events associated with itraconazole in 189 patients on chronic therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 1990 , 26, 561-6	5.1	169
32	Restriction endonuclease analysis of total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically diverse origin. <i>Journal of Infectious Diseases</i> , 1990 , 162, 1151-8	7	98
31	Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. <i>Journal of the American Academy of Dermatology</i> , 1990 , 23, 593-601	4.5	75
30	Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis. <i>Journal of the American Academy of Dermatology</i> , 1990 , 23, 602-7	4.5	57
29	Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. <i>Clinical Infectious Diseases</i> , 1990 , 12, 1147-201	11.6	663

(1987-1990)

28	Comparison of Guizotia abyssinica seed extract (birdseed) agar with conventional media for selective identification of Cryptococcus neoformans in patients with acquired immunodeficiency syndrome. <i>Journal of Clinical Microbiology</i> , 1990 , 28, 2565-7	9.7	19
27	Oral Itraconazole Therapy of Cryptococcal Meningitis and Cryptococcosis in Patients with AIDS 1990 , 305-324		9
26	Immunoassay of Aflatoxin in Food and Human Tissue. <i>Toxin Reviews</i> , 1989 , 8, 69-79		5
25	Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis. <i>Archives of Internal Medicine</i> , 1989 , 149, 2301		127
24	Clinical features of peritoneal tuberculosis. <i>Journal of Infectious Diseases</i> , 1989 , 160, 344-5	7	2
23	Treatment of invasive aspergillosis with itraconazole. <i>American Journal of Medicine</i> , 1989 , 86, 791-800	2.4	345
22	Transmission of Epstein-Barr virus by a transplanted kidney, with activation by OKT3 antibody. <i>Transplantation</i> , 1989 , 48, 141-4	1.8	14
21	Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study. <i>Journal of Clinical Microbiology</i> , 1989 , 27, 1352-6	9.7	30
20	Measurement of aflatoxin in Nigerian sera by enzyme-linked immunosorbent assay. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1988 , 82, 169-71	2	15
19	Eradication of Low-Level Methicillin-Resistant Staphylococcus aureus Skin Colonization with Topical Mupirocin. <i>Infection Control and Hospital Epidemiology</i> , 1988 , 9, 261-263	2	10
18	Myocarditis complicating ethylene glycol poisoning in the absence of neurological features. <i>Postgraduate Medical Journal</i> , 1988 , 64, 867-70	2	8
17	An ELISA method for the rapid and simple determination of aflatoxin in human serum. <i>Food Additives and Contaminants</i> , 1988 , 5, 609-19		16
16	Analysis of UK sera for aflatoxin by enzyme-linked immunosorbent assay. <i>Human Toxicology</i> , 1988 , 7, 353-6		21
15	Infant with two relapses of group B streptococcal sepsis documented by DNA restriction enzyme analysis. <i>Pediatric Infectious Disease Journal</i> , 1988 , 7, 729-32	3.4	17
14	Eradication of low-level methicillin-resistant Staphylococcus aureus skin colonization with topical mupirocin. <i>Infection Control and Hospital Epidemiology</i> , 1988 , 9, 261-3	2	12
13	Detrimental effect of propylene glycol on natural killer cell and neutrophil function. <i>Journal of Pharmacy and Pharmacology</i> , 1987 , 39, 236-8	4.8	9
12	Idiopathic oedema and diuretics. Postgraduate Medical Journal, 1987, 63, 25-6	2	3
11	Skin rash after triple vaccine. <i>Archives of Disease in Childhood</i> , 1987 , 62, 510-1	2.2	5

10	Neuralgic amyotrophy due to parvovirus infection. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1987 , 50, 641-2	5.5	23
9	Whole blood exchange as treatment for legionellosis. <i>Lancet, The</i> , 1987 , 1, 227	40	3
8	Invasive pulmonary aspergillosis diagnosed by blood culture and successfully treated. <i>British Journal of Diseases of the Chest</i> , 1987 , 81, 300-4		6
7	Death due to carbamazepine self-poisoning: remedies reviewed. <i>Human Toxicology</i> , 1985 , 4, 255-60		26
6	Colouring agents in medicine for asthmatic children. <i>Lancet, The</i> , 1985 , 1, 461-2	40	
5	Further problems with theophylline. <i>Lancet, The</i> , 1984 , 1, 223	40	2
4	Chronic Aspergillosis 319-331		2
3	The Global Incidence of Fungal Keratitis. SSRN Electronic Journal,	1	5
2	Aspergillus fumigatus catalases: cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases		2
1	Platelet size as a predictor for severity and mortality in COVID-19 patients: a systematic review and mortality	eta-ana	aly≰is